Navigation Links
HUYA Biosciences Establishes Strategic Partnership with Sun Yat-sen University's School of Pharmaceutical Sciences
Date:8/30/2010

SAN DIEGO, Aug. 30 /PRNewswire/ -- HUYA Bioscience International, a company at the forefront of globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the School of Pharmaceutical Sciences at Sun Yat-sen University (SYSU).  The collaborative agreement expands HUYA's foothold in Southern China, aiming to accelerate the development of novel drugs arising from the school's research efforts.

The agreement provides HUYA with access to and first review of certain novel therapeutic candidates owned or controlled by SYSU's School of Pharmaceutical Sciences.  Correspondingly, the school gains access to HUYA's expertise in drug development as well as its global network of pharmaceutical partners.

HUYA is one of the first companies to have recognized China's potential to help meet the global needs for new preclinical and clinical stage compounds.  This partnership is one of a series of collaborations that HUYA has established with leading academic and commercial R&D organizations throughout China in order to bring promising new drugs to global markets.  The company has pioneered in-licensing clinical stage compounds from China and is co-developing them concurrently in the U.S. and China with international partners.

The School of Pharmaceutical Sciences at SYSU, a prominent school in southern China, has the top per-capita research funding among China's pharmaceutical colleges and the capabilities to perform cutting-edge research as well as preclinical and clinical studies.  Research results at the school have been recognized internationally and have won numerous national and provincial awards, including China's state funding for Key Projects on Innovative Drug Discovery. These activities have provided rich sources of novel drug candidates.

"The alliance with the School of Pharmaceutical Sciences at SYSU bolsters our collaborative relationships with the school's outstanding faculty and researchers," said Mireille Gingras, Ph.D., President and CEO of HUYA.  "We believe our combined efforts will not only benefit the growth of both organizations, but also yield product opportunities of high potential to meet global medical needs."

"Our school is committed to internationalizing and commercializing the achievements of our research work," remarked Professor Min Huang, Ph.D., Dean of SYSU's School of Pharmaceutical Sciences.  "We are very pleased to join forces with the HUYA team to reach the goals by sharing our respective expertise and co-developing promising compounds."

ABOUT HUYA BIOSCIENCE INTERNATIONALHUYA is the leader in global co-development of pharmaceutical products originating in China. With six offices strategically located in China, the most comprehensive Chinese compound portfolio, and a fast growing number of exclusive agreements with premier Chinese research and development organizations, HUYA has pioneered the most innovative and productive approach to U.S.-China pharmaceutical co-development.  HUYA offers Western pharmaceutical companies efficient access to innovative drug opportunities and reduces complexity in making deals in China.  The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China.  Additional information about the company is available at www.huyabio.com.

ABOUT THE SCHOOL OF PHARMACEUTICAL SCIENCES, SUN YAT-SEN UNIVERSITY The School of Pharmaceutical Sciences, Sun Yat-sen University (SYSU) was established in 2002 as the first school newly formed after the combination of two universities--SYSU and SYSU of Medicinal Sciences.  It thus leverages all the medicinal research resources from both universities.  In order to develop into a national center for innovative drug research, development and evaluation as well as a training base for professionals in pharmacy, the school has been enriching its disciplines, recruiting outstanding teaching and research personnel, strengthening its infrastructure and logistics, and fostering a culture of creativity.  Through these efforts the school has achieved remarkable results including many award-winning projects.  It has also earned a key leading role in building the Southern China Center for Innovative Pharmaceuticals sponsored by the Guangdong Province.  For more information, visit http://sps.sysu.edu.cn.CONTACT:USA:Yung-Chih Wang, Ph.D., MBADirector of Corporate DevelopmentHUYA Bioscience International, LLC+1.858.798.8800ywang@huyabio.comChina:Qing (Vicky) Xia, MS, MBAScientific Research ManagerHUYA Bioscience International, LLC+86.21.51323312vxia@huyabio.comMedia Contact:Juliet Travis+1.510.452.3771juliet@travispr.com
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
2. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
3. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
4. SeqWrights Partnership with EraGen Biosciences Contributes to FDA Market Clearance Success
5. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
8. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
11. Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):